Free Newsletter
Venture group targets tech transfer deals in Texas
Emergent Technologies garnered $27.1 million in venture capital to license biotech research programs from the University of Texas. ETI has been operating in Texas for several years now. It specializes in identifying promising biotech research, licensing the technology and then spawning small start-up companies to advance the work. The company typically makes relatively small investments in each start-up and looks to larger pharma companies to come in and partner with them, providing much of the money necessary to grow the companies. Texas has lagged behind a large number of states that have seen their university research explode in recent years. The University of Florida system, meanwhile, has been one of the most active in the licensing arena.
- here's the report from the Austin American-Statesman
ALSO: A collaborative of scientists from South Florida and Latin America have begun seeking partners to advance their work in genomics. Report
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


